New Piperazine Derivatives of 6-Acetyl-7-hydroxy-4-methylcoumarin as 5-HT1A Receptor Agents

Int J Mol Sci. 2023 Feb 1;24(3):2779. doi: 10.3390/ijms24032779.

Abstract

A series of 15 new derivatives of 6-acetyl-7-hydroxy-4-methylcoumarin containing a piperazine group were designed with the help of computational methods and were synthesized to study their affinity for the serotonin 5-HT1A and 5-HT2A receptors. Among them, 6-acetyl-7-{4-[4-(3-bromophenyl)piperazin-1-yl]butoxy}-4-methylchromen-2-one (4) and 6-acetyl-7-{4-[4-(2-chlorophenyl)piperazin-1-yl]butoxy}-4-methylchromen-2-one (7) exhibited excellent activity for 5-HT1A receptors with Ki values 0.78 (0.4-1.4) nM and 0.57 (0.2-1.3) nM, respectively, comparable to the Ki values of 8-OH-DPAT (0.25 (0.097-0.66) nM). The equilibrium dissociation constant values of the tested compounds showed differential intrinsic activities of the agonist and antagonist modes.

Keywords: 6-acetyl-7-hydroxy-4-methylcoumarin; CNS activity; crystal structure; piperazine; serotonin receptors.

MeSH terms

  • Heterocyclic Compounds*
  • Piperazines / pharmacology
  • Receptor, Serotonin, 5-HT1A
  • Receptor, Serotonin, 5-HT2A
  • Receptors, Serotonin
  • Receptors, Serotonin, 5-HT1
  • Serotonin*

Substances

  • Serotonin
  • Receptor, Serotonin, 5-HT1A
  • 7-hydroxy-4-methylcoumarin
  • Receptors, Serotonin
  • Receptors, Serotonin, 5-HT1
  • Heterocyclic Compounds
  • Piperazines
  • Receptor, Serotonin, 5-HT2A